[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-198489-105":53,"doc-detail-198489-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","patient-centered-prescription-model-pcp-model-application-for-improving-medication-adherence-in-multimorbidity-patients","Patient-Centered Prescription Model - PCP model application for improving medication adherence in multimorbidity patients","","Patient-Centered Prescription (PCP) is presented as a multidimensional assessment and decision framework to improve therapeutic adherence in patients with multimorbidity. The model integrates patient-centered, diagnosis-centered, and drug-centered evaluations: it defines overall therapeutic goals such as survival, functional status, and symptom control, while tailoring targets to each diagnosis and each prescribed medication. Medication selection is supported by benefit/risk review, with strategies including deprescribing, switching high-risk therapies, and simplifying dosing. A treatment plan is built through communication and consensus with the patient and/or main caregiver, combining motivational interviewing, counseling, and an individualized dosage system to support discharge and community dispensing.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":11,"@type":70,"position":76},"https://docshare.wps.com/template/presentations/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/patient-centered-prescription-model-pcp-model-application-for-improving-medication-adherence-in-multimorbidity-patients/198489/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/patient-centered-prescription-model-pcp-model-application-for-improving-medication-adherence-in-multimorbidity-patients/198489.png","ImageObject",442,249,{"name":88,"@type":89},"Sarah ","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-11","2026-09-04",true,{"@type":98,"interactionType":99,"userInteractionCount":47},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What is the core structure of the Patient-Centered Prescription model?","Question",{"text":108,"@type":109},"It combines patient-centered assessment, diagnosis-centered assessment, and drug-centered assessment to define goals and tailor decisions to the patient’s overall and clinical needs.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"How does the model improve medication adherence in practice?",{"text":113,"@type":109},"It emphasizes shared communication of the treatment plan with the patient and/or main caregiver and provides patient support such as motivational interviewing, counseling, and an individualized dosage system for dispensing.",{"name":115,"@type":106,"acceptedAnswer":116},"Which medication optimization actions are highlighted in the case application?",{"text":117,"@type":109},"The model includes deprescribing strategies, switching high-risk medications, and simplifying dosing regimens based on clinical benefit/risk review.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},198489,1788481609,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":8,"category_name":11,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":47,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":135,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":125,"read_time":76},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","|  | How to cite this article:\u003Cbr>González-Bueno J, Calvo-Cidoncha E, Sevilla-Sánchez D, Molist-Brunet N, Espaulella-Panicot J, Codina-Jané C. Patient-Centered Prescription Model to improve therapeutic adherence in patients with multimorbidity.\u003Cbr>Farm Hosp. 2018;42(3):128-134 .\u003Cbr>|\n| --- | --- |\n\n| KEYWORDS\u003Cbr>Medication adherence; Inappropriate prescribing; Multimorbidity; Polypharmacy; Patient-centered care. |\n| --- |\n| PALABRAS CLAVE\u003Cbr>Adherencia terapéutica; Prescripción inadecuada;\u003Cbr>Multimorbilidad; Polifarmacia; Atención centrada en el paciente. |\n\n| | PATIENT-Centered Assessment\u003Cbr>• A multidimensional approach (clinical, functional, cognitive and social situation)\u003Cbr>• Determining the overall therapeutic goal: survival, functionality, symptom control.\u003Cbr>• Decisions shared with the patient and/or main caregiver.\u003Cbr>DIAGNOSIS-Centered Assessment\u003Cbr>• Identification of health problems and drugs prescribed for each of them.\u003Cbr>• Adaptation of therapeutic goals to the objective of each drug.\u003Cbr>DRUG-Centered Assessment\u003Cbr>• Adaptation of the medications prescribed to the clinical situation of the patient through a review of the benefit/risk of the drugs.\u003Cbr>TREATMENT PLAN\u003Cbr>• Communication and consensus of the treatment plan with the patient and/or main caregiver. |\n| --- | --- |\n\n|  |  | Application of the PCP model for enhancing medication adherence.\u003Cbr>A case report |  |  |\n| --- | --- | --- | --- | --- |\n| Conditions at baseline | Drug therapy at baseline | PATIENT-centered Assessment\u003Cbr>Treatment objective: Maintaining functionality | DIAGNOSIS & DRUG-centered Assessment\u003Cbr>a. Deprescribing strategies\u003Cbr>b. Switching of high-risk medications\u003Cbr>c. Dosing simplification | TREATMENT PLAN |\n| Hypertension | Amlodipine 5mg/12 hs. Doxazosin 4mg/12hs Hydrochlorothiazide 25mg/24hs. | Non-adherence barriers identified through the ARMS questionnaire (see details in Figure 4):\u003Cbr>High medication regimen complexity. Medication-related Adverse events. Inadequate knowledge and/or beliefs about drug therapy. | Lower limb oedema: HTN 130/80 mmHg\u003Cbr>Manidipine 10mg/24 hs.a,b,c Doxazosin 8mg/24 hs.c\u003Cbr>GFR 22ml/min: Urate 8.0 mg/dl Discontinue Hydrochlorothiazide 25mg/24 hs.a,b | Hospital setting: Motivational interviewing and counselling with patient and main caregiver + drug treatment plan provided at discharge. Prescription of a Personalized Dosage System.\u003Cbr>Community pharmacy: Educational reinforcement with patient and main caregiver Medication dispensing through Personalized Dosage System. |\n| Coronary Heart Disease | ASA 100mg/24hs. Bisoprolol 5mg/24 hs. Isosorbide mononitrate 50mg/12 hs.\u003Cbr>Ranolazine 375mg/12 hs. Atorvastatin 40mg/24 hs. |  | Controversial efficacy: Barthel 55/100\u003Cbr>Discontinue Ranolazine 375mg/12 hs.a\u003Cbr>CL 138 mg/dl; HDL 40mg/dl; LDL 50mg/dl\u003Cbr>Simvastatin 40mg/24 hs.a |  |\n| Congestive Heart Failure | Atenolol 50mg/12 hs. Furosemide 40mg/8 hs. |  | No changes. |  |\n| Diabetes Mellitus II | Repaglinide 0.5mg/12 hs. |  | HbA1c 6.5%;\u003Cbr>Glycemia: 86-140-130 Discontinue Repaglinide 0.5mg/12 hs.a,b |  |\n| Hyperuricemia\u003Cbr>(asymptomatic) | Allopurinol 100mg/24 hs. |  | Urate 8.0 mg/dl\u003Cbr>Discontinue hydrochlorothiazide\u003Cbr>Discontinue Allopurinol 100mg/24 hs.a |  |\n| Chronic Renal Impairment | No specific treatment. |  | No changes. |  |\n| Peptic Ulcer | Omeprazole 20mg/24 hs. |  | No changes. |  |\n| COPD | Ipratropium 40mcg/8 hs. |  | Tiotropium 5mcg/24 hs.c |  |\n| Gonarthrosis | Paracetamol 1g/8 hs. Calcium / Vitamin D 600mg/400IU/24 hs. |  | Primary prevention for osteoporotic fracture\u003Cbr>Discontinue Calcium / Vitamin D 600mg/400IU/24 hs. |  |\n| Insomnia | Lorazepam 1mg/24 hs.+ 1 mg/prn. |  | Lorazepam 1 mg/prna,b,c |  |\n|  | MRCI: 52.5 |  | MRCI: 31.5 |  |\n\n| 1. How often do you forget to take your medicine?a | Some |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| 2. How often do you decide not to take your medicine?a | Some |  |  |  |  |\n| 3. How often do you forget to get prescriptions filled?b ","cbCaihbMbzcxuHLW","https://ap.wps.com/l/cbCaihbMbzcxuHLW","pdf",228886,7,"English","# Patient-Centered Prescription Model\n## Assessment approach (patient, diagnosis, drug)\n## Treatment plan and shared decision-making\n## Application in a case report\n## Baseline conditions, therapies, and adherence barriers\n## ARMS questionnaire items","[{\"question\":\"What is the core structure of the Patient-Centered Prescription model?\",\"answer\":\"It combines patient-centered assessment, diagnosis-centered assessment, and drug-centered assessment to define goals and tailor decisions to the patient’s overall and clinical needs.\"},{\"question\":\"How does the model improve medication adherence in practice?\",\"answer\":\"It emphasizes shared communication of the treatment plan with the patient and/or main caregiver and provides patient support such as motivational interviewing, counseling, and an individualized dosage system for dispensing.\"},{\"question\":\"Which medication optimization actions are highlighted in the case application?\",\"answer\":\"The model includes deprescribing strategies, switching high-risk medications, and simplifying dosing regimens based on clinical benefit/risk review.\"}]","Patient-Centered Prescription Model - PCP model application for improving medication adherence in multimorbidity patients | PDF"]